Amgen Begins ARROW Trial Based On Results From Phase 1/2 CHAMPION Study

(RTTNews) - Amgen (AMGN) announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. FDA approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent.

The trial was initiated based on results from the Phase 1/2 CHAMPION study. In the Phase 2 portion of the CHAMPION study, the overall response rate was 77 percent. The clinical benefit rate was 84 percent.